Emory University;DANA-FARBER CANCER INSTITUTE, INC.
发明人:
FREEMAN, Gordon J.,AHMED, Rafi,JONES, Timothy D.,CARR, Francis J.,GREGSON, James P.
申请号：
AU2019246763
公开号：
AU2019246763A1
申请日:
2019.10.08
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
#$%^&*AU2019246763A120191031.pdf#####Abstract The present invention is based, in part, on the identification of novel human anti-PD-1, PDLI, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein. 10191856_1 (GHMatters) P86720.AU.432/42 Figure 9. Comparison of Composite, human Antibodies Activities to Mouse Reference Antibody (Figure 9A) Human PD-1 Competition ELISA: Competition Assay- Sample v BiotinylatedEH12.2H7 0.9 0.8 -- Mouse 0.7 __V3NK3 0. -A- V H3NK4 M 0.5 -*04-VH4NK3 0.4 o 0.3 -- VH4NK4 0.2 0.1 101 0.01 0.1 1 10 Sample ug/ml
